Ping-Ching Hsu
Concepts (534)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Helicobacter pylori | 11 | 2014 | 66 | 2.170 |
Why?
| Helicobacter Infections | 9 | 2014 | 64 | 2.070 |
Why?
| Carcinoma, Non-Small-Cell Lung | 6 | 2024 | 154 | 1.340 |
Why?
| Smoking | 5 | 2016 | 506 | 1.310 |
Why?
| Hepatitis B, Chronic | 7 | 2014 | 17 | 1.300 |
Why?
| Tumor Necrosis Factor-alpha | 6 | 2014 | 388 | 1.230 |
Why?
| Hepatitis B virus | 5 | 2014 | 26 | 1.110 |
Why?
| Menthol | 2 | 2016 | 17 | 1.070 |
Why?
| Lung Neoplasms | 7 | 2024 | 601 | 1.060 |
Why?
| Metabolome | 2 | 2016 | 92 | 0.900 |
Why?
| Nicotine | 2 | 2016 | 182 | 0.880 |
Why?
| Carcinoma, Hepatocellular | 8 | 2014 | 196 | 0.840 |
Why?
| Liver Neoplasms | 9 | 2014 | 331 | 0.830 |
Why?
| Middle Aged | 48 | 2024 | 12356 | 0.800 |
Why?
| Spermatozoa | 3 | 2007 | 23 | 0.760 |
Why?
| Apoptosis | 6 | 2014 | 1093 | 0.730 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 1000 | 0.690 |
Why?
| Lymphocyte Activation | 4 | 2024 | 171 | 0.690 |
Why?
| Peptic Ulcer | 3 | 2010 | 14 | 0.690 |
Why?
| Aged | 37 | 2024 | 9505 | 0.670 |
Why?
| Induction Chemotherapy | 1 | 2019 | 60 | 0.650 |
Why?
| TNF-Related Apoptosis-Inducing Ligand | 5 | 2012 | 20 | 0.650 |
Why?
| Male | 58 | 2024 | 25572 | 0.640 |
Why?
| Membrane Glycoproteins | 3 | 2005 | 244 | 0.630 |
Why?
| Metabolomics | 2 | 2016 | 133 | 0.620 |
Why?
| Cisplatin | 3 | 2019 | 275 | 0.610 |
Why?
| Female | 52 | 2024 | 26829 | 0.590 |
Why?
| Proton Pump Inhibitors | 2 | 2010 | 84 | 0.590 |
Why?
| Apoptosis Regulatory Proteins | 5 | 2010 | 85 | 0.580 |
Why?
| Genetic Predisposition to Disease | 4 | 2024 | 508 | 0.570 |
Why?
| Hepatitis B Core Antigens | 2 | 2014 | 7 | 0.560 |
Why?
| Polychlorinated Biphenyls | 3 | 2007 | 25 | 0.560 |
Why?
| Glucuronates | 1 | 2016 | 22 | 0.550 |
Why?
| Humans | 70 | 2024 | 50201 | 0.530 |
Why?
| Testis | 2 | 2007 | 65 | 0.530 |
Why?
| Adult | 35 | 2024 | 13486 | 0.530 |
Why?
| Up-Regulation | 7 | 2014 | 446 | 0.520 |
Why?
| Gastritis | 2 | 2007 | 32 | 0.520 |
Why?
| Gastrointestinal Hemorrhage | 7 | 2014 | 79 | 0.510 |
Why?
| Programmed Cell Death 1 Receptor | 2 | 2012 | 40 | 0.490 |
Why?
| Endoscopy, Digestive System | 2 | 2012 | 51 | 0.460 |
Why?
| Anti-Bacterial Agents | 6 | 2014 | 744 | 0.450 |
Why?
| Aged, 80 and over | 14 | 2024 | 3158 | 0.440 |
Why?
| Disease Models, Animal | 3 | 2014 | 1419 | 0.440 |
Why?
| Immunity, Innate | 1 | 2014 | 105 | 0.430 |
Why?
| Esophageal and Gastric Varices | 6 | 2012 | 14 | 0.420 |
Why?
| Lymphoma, B-Cell, Marginal Zone | 2 | 2010 | 24 | 0.420 |
Why?
| Cholecystolithiasis | 1 | 2012 | 1 | 0.420 |
Why?
| Bile Duct Diseases | 1 | 2012 | 11 | 0.420 |
Why?
| Choledocholithiasis | 1 | 2012 | 13 | 0.410 |
Why?
| Taiwan | 7 | 2014 | 22 | 0.410 |
Why?
| Antigens, Bacterial | 2 | 2010 | 54 | 0.410 |
Why?
| Duodenal Ulcer | 3 | 2009 | 12 | 0.400 |
Why?
| Tobacco Products | 2 | 2015 | 125 | 0.390 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2012 | 123 | 0.380 |
Why?
| Galectin 3 | 1 | 2011 | 14 | 0.370 |
Why?
| Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2010 | 3 | 0.370 |
Why?
| Membrane Microdomains | 1 | 2010 | 12 | 0.370 |
Why?
| T-Lymphocytes | 2 | 2010 | 329 | 0.360 |
Why?
| NF-kappa B | 3 | 2010 | 315 | 0.360 |
Why?
| Ticlopidine | 1 | 2010 | 55 | 0.350 |
Why?
| Arthritis, Rheumatoid | 1 | 2011 | 105 | 0.350 |
Why?
| Gastric Juice | 1 | 2010 | 6 | 0.350 |
Why?
| Chemotaxis, Leukocyte | 2 | 2007 | 13 | 0.350 |
Why?
| Macrophage Inflammatory Proteins | 2 | 2007 | 5 | 0.350 |
Why?
| Endoscopy, Gastrointestinal | 6 | 2012 | 76 | 0.340 |
Why?
| alpha 1-Antitrypsin | 1 | 2010 | 14 | 0.340 |
Why?
| Esophagitis | 1 | 2009 | 9 | 0.330 |
Why?
| Bacterial Proteins | 3 | 2010 | 372 | 0.330 |
Why?
| Stomach Neoplasms | 2 | 2010 | 187 | 0.330 |
Why?
| Antigens, CD | 1 | 2010 | 216 | 0.330 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2010 | 174 | 0.320 |
Why?
| Serologic Tests | 1 | 2008 | 25 | 0.320 |
Why?
| Neoplasm Staging | 5 | 2021 | 749 | 0.320 |
Why?
| Breath Tests | 1 | 2008 | 38 | 0.320 |
Why?
| Anti-Ulcer Agents | 2 | 2005 | 21 | 0.310 |
Why?
| Signal Transduction | 7 | 2014 | 1612 | 0.310 |
Why?
| Urea | 1 | 2008 | 80 | 0.310 |
Why?
| Sulfoxides | 2 | 2005 | 20 | 0.310 |
Why?
| Antibodies, Antinuclear | 2 | 2007 | 14 | 0.310 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2011 | 484 | 0.310 |
Why?
| Chemokines, CC | 2 | 2007 | 7 | 0.310 |
Why?
| Benzimidazoles | 2 | 2005 | 49 | 0.310 |
Why?
| Atherosclerosis | 1 | 2010 | 210 | 0.300 |
Why?
| Acrylamides | 2 | 2024 | 7 | 0.300 |
Why?
| Gastric Mucosa | 2 | 2007 | 48 | 0.300 |
Why?
| HLA-DR2 Antigen | 1 | 2007 | 1 | 0.300 |
Why?
| Prospective Studies | 9 | 2019 | 2396 | 0.290 |
Why?
| Cell Proliferation | 2 | 2014 | 987 | 0.290 |
Why?
| Amoxicillin | 4 | 2014 | 20 | 0.290 |
Why?
| Liver | 7 | 2014 | 1122 | 0.290 |
Why?
| Receptors, Chemokine | 1 | 2007 | 13 | 0.290 |
Why?
| Enzyme Activation | 5 | 2010 | 270 | 0.290 |
Why?
| Liver Cirrhosis | 6 | 2012 | 228 | 0.280 |
Why?
| Mutation | 2 | 2024 | 1288 | 0.280 |
Why?
| Mass Screening | 1 | 2010 | 348 | 0.270 |
Why?
| Pseudarthrosis | 1 | 2006 | 1 | 0.270 |
Why?
| Arthritis, Psoriatic | 1 | 2006 | 9 | 0.270 |
Why?
| Lupus Erythematosus, Systemic | 2 | 2004 | 68 | 0.270 |
Why?
| Hepatitis C, Chronic | 1 | 2007 | 86 | 0.270 |
Why?
| Flame Retardants | 1 | 2006 | 1 | 0.270 |
Why?
| Polybrominated Biphenyls | 1 | 2006 | 1 | 0.270 |
Why?
| Epididymis | 1 | 2006 | 7 | 0.270 |
Why?
| Phenyl Ethers | 1 | 2006 | 5 | 0.270 |
Why?
| Monocytes | 4 | 2014 | 131 | 0.260 |
Why?
| Spinal Fractures | 1 | 2006 | 37 | 0.260 |
Why?
| Peroxidase | 1 | 2005 | 15 | 0.250 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2010 | 127 | 0.250 |
Why?
| Viral Core Proteins | 1 | 2005 | 6 | 0.250 |
Why?
| Gallstones | 4 | 2009 | 13 | 0.240 |
Why?
| DNA | 3 | 2015 | 543 | 0.240 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2007 | 185 | 0.240 |
Why?
| Naphthoquinones | 1 | 2004 | 10 | 0.240 |
Why?
| Mitochondria, Liver | 1 | 2005 | 69 | 0.240 |
Why?
| Aniline Compounds | 1 | 2024 | 42 | 0.230 |
Why?
| Drug Hypersensitivity | 1 | 2024 | 37 | 0.230 |
Why?
| Hepacivirus | 1 | 2005 | 105 | 0.230 |
Why?
| Immunologic Factors | 1 | 2005 | 112 | 0.230 |
Why?
| Morpholines | 1 | 2024 | 66 | 0.230 |
Why?
| Alleles | 1 | 2024 | 253 | 0.230 |
Why?
| Antiviral Agents | 3 | 2014 | 168 | 0.220 |
Why?
| Cachexia | 1 | 2003 | 25 | 0.220 |
Why?
| Young Adult | 5 | 2019 | 4052 | 0.220 |
Why?
| Enzyme Inhibitors | 1 | 2005 | 378 | 0.220 |
Why?
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2004 | 122 | 0.220 |
Why?
| Triiodothyronine | 1 | 2003 | 29 | 0.220 |
Why?
| Sex Factors | 4 | 2016 | 700 | 0.210 |
Why?
| Reactive Oxygen Species | 4 | 2007 | 406 | 0.210 |
Why?
| Carrier Proteins | 1 | 2005 | 302 | 0.210 |
Why?
| Antibodies, Bispecific | 1 | 2024 | 71 | 0.210 |
Why?
| Follow-Up Studies | 8 | 2020 | 2188 | 0.210 |
Why?
| Antibodies, Monoclonal | 2 | 2020 | 459 | 0.210 |
Why?
| Risk Assessment | 5 | 2016 | 1255 | 0.210 |
Why?
| Pyrimidines | 2 | 2024 | 192 | 0.210 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2004 | 157 | 0.200 |
Why?
| Lipopolysaccharides | 5 | 2008 | 196 | 0.200 |
Why?
| 2-Pyridinylmethylsulfinylbenzimidazoles | 3 | 2014 | 19 | 0.200 |
Why?
| Metronidazole | 2 | 2012 | 27 | 0.200 |
Why?
| Animals | 12 | 2014 | 13141 | 0.190 |
Why?
| Clarithromycin | 3 | 2014 | 38 | 0.190 |
Why?
| Organometallic Compounds | 2 | 2012 | 44 | 0.190 |
Why?
| Cells, Cultured | 6 | 2015 | 1587 | 0.190 |
Why?
| Treatment Outcome | 12 | 2021 | 5203 | 0.190 |
Why?
| Age Factors | 4 | 2016 | 1096 | 0.190 |
Why?
| Mice | 8 | 2014 | 5673 | 0.190 |
Why?
| Sigmoidoscopy | 2 | 2014 | 10 | 0.190 |
Why?
| Cross-Sectional Studies | 3 | 2016 | 1580 | 0.190 |
Why?
| Colorectal Neoplasms | 1 | 2004 | 255 | 0.190 |
Why?
| Virus Replication | 2 | 2014 | 138 | 0.190 |
Why?
| Reproducibility of Results | 2 | 2016 | 1195 | 0.190 |
Why?
| Cohort Studies | 2 | 2019 | 1414 | 0.180 |
Why?
| Drug Therapy, Combination | 7 | 2013 | 382 | 0.180 |
Why?
| Adenine | 2 | 2013 | 31 | 0.170 |
Why?
| Interferon-gamma | 3 | 2012 | 176 | 0.170 |
Why?
| Sulfones | 1 | 2019 | 24 | 0.170 |
Why?
| Chemoradiotherapy | 1 | 2020 | 43 | 0.170 |
Why?
| Salvage Therapy | 1 | 2020 | 136 | 0.170 |
Why?
| Recurrence | 6 | 2012 | 660 | 0.170 |
Why?
| Oncogene Proteins, Fusion | 1 | 2019 | 59 | 0.170 |
Why?
| Prognosis | 6 | 2021 | 1963 | 0.160 |
Why?
| Genotype | 3 | 2024 | 542 | 0.160 |
Why?
| Multivariate Analysis | 4 | 2016 | 581 | 0.160 |
Why?
| Sphincterotomy, Endoscopic | 3 | 2009 | 15 | 0.160 |
Why?
| Adolescent | 5 | 2016 | 6459 | 0.150 |
Why?
| Administration, Oral | 1 | 2019 | 432 | 0.150 |
Why?
| Platelet Aggregation | 2 | 2010 | 71 | 0.150 |
Why?
| Somatostatin | 2 | 2008 | 31 | 0.140 |
Why?
| Pancreatitis | 2 | 2008 | 58 | 0.140 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 579 | 0.140 |
Why?
| Mitogen-Activated Protein Kinases | 2 | 2010 | 153 | 0.140 |
Why?
| Carcinoma, Squamous Cell | 1 | 2020 | 330 | 0.140 |
Why?
| Sensitivity and Specificity | 2 | 2010 | 871 | 0.140 |
Why?
| Risk Factors | 5 | 2014 | 3644 | 0.140 |
Why?
| Nadolol | 2 | 2008 | 3 | 0.140 |
Why?
| Caspase 9 | 2 | 2007 | 13 | 0.130 |
Why?
| Dose-Response Relationship, Drug | 5 | 2007 | 1356 | 0.130 |
Why?
| Alcohol Drinking | 2 | 2009 | 221 | 0.130 |
Why?
| Caspase 3 | 2 | 2007 | 93 | 0.130 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2015 | 409 | 0.130 |
Why?
| Severity of Illness Index | 5 | 2012 | 959 | 0.130 |
Why?
| Cell Line, Tumor | 3 | 2010 | 1390 | 0.130 |
Why?
| Rats, Sprague-Dawley | 4 | 2014 | 1581 | 0.120 |
Why?
| Animals, Newborn | 2 | 2007 | 367 | 0.120 |
Why?
| Injections, Intraperitoneal | 2 | 2007 | 57 | 0.120 |
Why?
| Membrane Potentials | 2 | 2006 | 117 | 0.120 |
Why?
| Sperm Count | 2 | 2006 | 10 | 0.120 |
Why?
| Sperm Motility | 2 | 2006 | 11 | 0.120 |
Why?
| Adenosine Diphosphate | 2 | 2004 | 21 | 0.120 |
Why?
| P-Selectin | 2 | 2004 | 32 | 0.120 |
Why?
| Guanine | 3 | 2014 | 40 | 0.120 |
Why?
| Caspases | 2 | 2005 | 104 | 0.120 |
Why?
| Toll-Like Receptor 9 | 1 | 2014 | 10 | 0.120 |
Why?
| Leukocytes | 2 | 2004 | 69 | 0.120 |
Why?
| Cyclooxygenase 2 Inhibitors | 1 | 2014 | 17 | 0.110 |
Why?
| Intestinal Polyps | 1 | 2014 | 7 | 0.110 |
Why?
| Tumor Suppressor Protein p53 | 2 | 2007 | 214 | 0.110 |
Why?
| PTEN Phosphohydrolase | 1 | 2014 | 53 | 0.110 |
Why?
| Thymidine | 1 | 2013 | 19 | 0.110 |
Why?
| Aryl Hydrocarbon Hydroxylases | 2 | 2011 | 74 | 0.110 |
Why?
| Organophosphonates | 1 | 2013 | 7 | 0.110 |
Why?
| Thromboembolism | 1 | 2014 | 54 | 0.110 |
Why?
| Mice, Inbred C57BL | 4 | 2013 | 1782 | 0.110 |
Why?
| Hysterectomy | 1 | 2014 | 88 | 0.110 |
Why?
| Immunocompetence | 1 | 2013 | 18 | 0.110 |
Why?
| Dobutamine | 2 | 2003 | 22 | 0.110 |
Why?
| Adrenergic beta-Agonists | 2 | 2003 | 41 | 0.110 |
Why?
| Chemokine CCL2 | 2 | 2003 | 67 | 0.110 |
Why?
| Toll-Like Receptor 3 | 1 | 2013 | 10 | 0.110 |
Why?
| Interferons | 1 | 2013 | 38 | 0.110 |
Why?
| Area Under Curve | 2 | 2012 | 178 | 0.110 |
Why?
| Warfarin | 1 | 2014 | 83 | 0.110 |
Why?
| Gene Frequency | 2 | 2011 | 96 | 0.110 |
Why?
| Secondary Prevention | 2 | 2010 | 79 | 0.110 |
Why?
| Cholangiopancreatography, Endoscopic Retrograde | 3 | 2009 | 90 | 0.110 |
Why?
| Cyclooxygenase 2 | 2 | 2014 | 43 | 0.110 |
Why?
| Pyrazoles | 1 | 2014 | 111 | 0.110 |
Why?
| Interleukin-6 | 2 | 2012 | 266 | 0.110 |
Why?
| ROC Curve | 2 | 2012 | 236 | 0.110 |
Why?
| Sulfonamides | 1 | 2014 | 125 | 0.110 |
Why?
| Protein Transport | 2 | 2010 | 183 | 0.110 |
Why?
| Rats | 4 | 2014 | 3277 | 0.100 |
Why?
| Ofloxacin | 1 | 2012 | 7 | 0.100 |
Why?
| Cell Line | 5 | 2012 | 1010 | 0.100 |
Why?
| Quality Control | 1 | 2013 | 95 | 0.100 |
Why?
| Cholecystectomy | 1 | 2012 | 29 | 0.100 |
Why?
| Flow Cytometry | 4 | 2014 | 475 | 0.100 |
Why?
| TNF Receptor-Associated Factor 6 | 1 | 2012 | 8 | 0.100 |
Why?
| Observer Variation | 1 | 2013 | 136 | 0.100 |
Why?
| Hepatitis B | 2 | 2010 | 23 | 0.100 |
Why?
| Cesarean Section | 1 | 2014 | 185 | 0.100 |
Why?
| Elasticity Imaging Techniques | 1 | 2012 | 28 | 0.100 |
Why?
| Blood Platelets | 2 | 2004 | 252 | 0.100 |
Why?
| Mitochondria | 2 | 2006 | 398 | 0.100 |
Why?
| Interleukins | 1 | 2012 | 32 | 0.100 |
Why?
| Pregnancy | 3 | 2014 | 2609 | 0.100 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2010 | 234 | 0.100 |
Why?
| Gene Expression Regulation | 4 | 2015 | 964 | 0.100 |
Why?
| Retrospective Studies | 4 | 2021 | 6190 | 0.100 |
Why?
| Mice, Inbred BALB C | 1 | 2012 | 296 | 0.100 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2013 | 326 | 0.100 |
Why?
| Spleen | 1 | 2012 | 170 | 0.100 |
Why?
| Tandem Mass Spectrometry | 1 | 2013 | 231 | 0.090 |
Why?
| Oligonucleotide Probes | 1 | 2011 | 20 | 0.090 |
Why?
| Anticoagulants | 1 | 2014 | 253 | 0.090 |
Why?
| Tetracycline | 1 | 2011 | 20 | 0.090 |
Why?
| Protein Kinase Inhibitors | 2 | 2024 | 205 | 0.090 |
Why?
| Nucleic Acid Hybridization | 1 | 2011 | 55 | 0.090 |
Why?
| Polymorphism, Restriction Fragment Length | 1 | 2011 | 66 | 0.090 |
Why?
| Immunohistochemistry | 2 | 2013 | 973 | 0.090 |
Why?
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2010 | 3 | 0.090 |
Why?
| Jurkat Cells | 1 | 2010 | 28 | 0.090 |
Why?
| Platelet Function Tests | 1 | 2010 | 17 | 0.090 |
Why?
| Polymorphism, Genetic | 2 | 2011 | 181 | 0.090 |
Why?
| Feasibility Studies | 1 | 2013 | 383 | 0.090 |
Why?
| Gene Expression Profiling | 1 | 2015 | 1029 | 0.090 |
Why?
| Drug Administration Schedule | 5 | 2013 | 369 | 0.090 |
Why?
| Organ Size | 2 | 2012 | 223 | 0.090 |
Why?
| Disease Progression | 3 | 2014 | 821 | 0.090 |
Why?
| Drug Interactions | 1 | 2010 | 208 | 0.090 |
Why?
| bcl-X Protein | 1 | 2010 | 53 | 0.090 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2010 | 75 | 0.090 |
Why?
| Lymphoma, B-Cell | 1 | 2010 | 61 | 0.090 |
Why?
| Areca | 1 | 2009 | 2 | 0.080 |
Why?
| Gallbladder Neoplasms | 1 | 2009 | 7 | 0.080 |
Why?
| Logistic Models | 2 | 2009 | 901 | 0.080 |
Why?
| Tumor Cells, Cultured | 2 | 2014 | 462 | 0.080 |
Why?
| Cell Differentiation | 1 | 2012 | 648 | 0.080 |
Why?
| bcl-2-Associated X Protein | 2 | 2007 | 53 | 0.080 |
Why?
| B-Lymphocytes | 1 | 2010 | 175 | 0.080 |
Why?
| Osteoclasts | 1 | 2012 | 424 | 0.080 |
Why?
| Body Mass Index | 2 | 2009 | 658 | 0.080 |
Why?
| Bilirubin | 2 | 2007 | 40 | 0.080 |
Why?
| Catechols | 1 | 2008 | 8 | 0.080 |
Why?
| Capsules | 1 | 2008 | 28 | 0.080 |
Why?
| Albumins | 1 | 2009 | 31 | 0.080 |
Why?
| DNA, Viral | 3 | 2014 | 133 | 0.080 |
Why?
| Endotoxins | 1 | 2009 | 31 | 0.080 |
Why?
| Antibodies, Bacterial | 1 | 2008 | 27 | 0.080 |
Why?
| Peritonitis | 1 | 2009 | 27 | 0.080 |
Why?
| Intestinal Mucosa | 2 | 2007 | 217 | 0.080 |
Why?
| Chi-Square Distribution | 1 | 2009 | 280 | 0.080 |
Why?
| Carbon Isotopes | 1 | 2008 | 71 | 0.080 |
Why?
| Nitric Oxide Synthase Type II | 1 | 2008 | 64 | 0.080 |
Why?
| Isosorbide Dinitrate | 1 | 2008 | 1 | 0.080 |
Why?
| B-Cell Activating Factor | 1 | 2008 | 3 | 0.080 |
Why?
| Prevalence | 2 | 2009 | 960 | 0.080 |
Why?
| Digestive System Surgical Procedures | 1 | 2008 | 32 | 0.080 |
Why?
| Adenomyoma | 1 | 2008 | 2 | 0.080 |
Why?
| Jejunal Neoplasms | 1 | 2008 | 4 | 0.080 |
Why?
| Dietary Fats | 1 | 2009 | 125 | 0.080 |
Why?
| Immunoglobulin G | 1 | 2008 | 184 | 0.080 |
Why?
| Antibody Specificity | 1 | 2007 | 35 | 0.070 |
Why?
| Ligands | 2 | 2006 | 203 | 0.070 |
Why?
| p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 96 | 0.070 |
Why?
| Phenotype | 1 | 2010 | 732 | 0.070 |
Why?
| Vasodilator Agents | 1 | 2008 | 98 | 0.070 |
Why?
| Adrenergic beta-Antagonists | 1 | 2008 | 106 | 0.070 |
Why?
| Radiopharmaceuticals | 1 | 2008 | 205 | 0.070 |
Why?
| Chemokine CCL20 | 1 | 2007 | 1 | 0.070 |
Why?
| Receptors, CCR6 | 1 | 2007 | 3 | 0.070 |
Why?
| Receptors, CXCR3 | 1 | 2007 | 3 | 0.070 |
Why?
| Receptors, CCR5 | 1 | 2007 | 6 | 0.070 |
Why?
| Survival Rate | 3 | 2020 | 906 | 0.070 |
Why?
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 178 | 0.070 |
Why?
| Immunologic Memory | 1 | 2007 | 29 | 0.070 |
Why?
| DNA Primers | 2 | 2004 | 207 | 0.070 |
Why?
| Models, Biological | 2 | 2008 | 722 | 0.070 |
Why?
| T-Lymphocyte Subsets | 1 | 2007 | 38 | 0.070 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2008 | 104 | 0.070 |
Why?
| Th1 Cells | 1 | 2007 | 53 | 0.070 |
Why?
| Interleukin-8 | 2 | 2005 | 86 | 0.070 |
Why?
| Chemotaxis | 2 | 2003 | 22 | 0.070 |
Why?
| Spondylitis, Ankylosing | 1 | 2006 | 9 | 0.070 |
Why?
| Time Factors | 2 | 2010 | 2909 | 0.070 |
Why?
| Inflammation Mediators | 1 | 2007 | 110 | 0.070 |
Why?
| Halogenated Diphenyl Ethers | 1 | 2006 | 1 | 0.070 |
Why?
| RNA, Messenger | 5 | 2014 | 1097 | 0.070 |
Why?
| Steroid 11-beta-Hydroxylase | 1 | 2006 | 1 | 0.070 |
Why?
| Hemostasis, Endoscopic | 1 | 2006 | 4 | 0.070 |
Why?
| Pilot Projects | 2 | 2005 | 703 | 0.070 |
Why?
| Ligation | 4 | 2008 | 62 | 0.070 |
Why?
| Macrophages | 1 | 2008 | 362 | 0.060 |
Why?
| Proto-Oncogene Proteins | 2 | 2008 | 150 | 0.060 |
Why?
| Gastroscopy | 1 | 2005 | 19 | 0.060 |
Why?
| Cytokines | 1 | 2009 | 607 | 0.060 |
Why?
| Ketotifen | 1 | 2005 | 2 | 0.060 |
Why?
| Leukotriene Antagonists | 1 | 2005 | 4 | 0.060 |
Why?
| Case-Control Studies | 3 | 2014 | 1145 | 0.060 |
Why?
| Histamine H1 Antagonists | 1 | 2005 | 10 | 0.060 |
Why?
| Diet | 1 | 2009 | 554 | 0.060 |
Why?
| Chromatin | 1 | 2006 | 138 | 0.060 |
Why?
| Caspase 8 | 1 | 2005 | 10 | 0.060 |
Why?
| Fas Ligand Protein | 1 | 2005 | 17 | 0.060 |
Why?
| BH3 Interacting Domain Death Agonist Protein | 1 | 2005 | 14 | 0.060 |
Why?
| Genes, Bacterial | 1 | 2005 | 64 | 0.060 |
Why?
| Quinolines | 1 | 2005 | 41 | 0.060 |
Why?
| Anti-Asthmatic Agents | 1 | 2005 | 29 | 0.060 |
Why?
| Chemokines | 1 | 2005 | 76 | 0.060 |
Why?
| Hydrolysis | 1 | 2005 | 63 | 0.060 |
Why?
| Acetates | 1 | 2005 | 49 | 0.060 |
Why?
| Stevens-Johnson Syndrome | 1 | 2024 | 4 | 0.060 |
Why?
| HLA-B Antigens | 1 | 2024 | 7 | 0.060 |
Why?
| Kaplan-Meier Estimate | 2 | 2021 | 463 | 0.060 |
Why?
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2004 | 17 | 0.060 |
Why?
| Anesthesia, Inhalation | 1 | 2004 | 12 | 0.060 |
Why?
| Cytochromes c | 1 | 2004 | 28 | 0.060 |
Why?
| Antineoplastic Agents | 2 | 2024 | 1176 | 0.060 |
Why?
| Cholesterol | 1 | 2005 | 148 | 0.060 |
Why?
| Midazolam | 1 | 2004 | 37 | 0.060 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2004 | 29 | 0.060 |
Why?
| Anesthetics, Intravenous | 1 | 2004 | 22 | 0.060 |
Why?
| Methyl Ethers | 1 | 2004 | 18 | 0.060 |
Why?
| Chronic Disease | 1 | 2007 | 568 | 0.060 |
Why?
| Gene Expression | 1 | 2007 | 612 | 0.060 |
Why?
| DNA Fragmentation | 1 | 2004 | 54 | 0.060 |
Why?
| Injections, Subcutaneous | 1 | 2024 | 51 | 0.060 |
Why?
| Receptors, Interleukin-2 | 1 | 2004 | 7 | 0.060 |
Why?
| Antibodies, Blocking | 1 | 2004 | 6 | 0.060 |
Why?
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 1 | 2004 | 6 | 0.060 |
Why?
| Patient Compliance | 1 | 2005 | 230 | 0.060 |
Why?
| Coculture Techniques | 1 | 2004 | 143 | 0.060 |
Why?
| Immunotoxins | 1 | 2004 | 6 | 0.060 |
Why?
| Administration, Intravenous | 1 | 2024 | 70 | 0.060 |
Why?
| Immunoglobulin Fc Fragments | 1 | 2004 | 11 | 0.060 |
Why?
| Tranexamic Acid | 1 | 2004 | 15 | 0.060 |
Why?
| Esophagoscopy | 1 | 2004 | 27 | 0.060 |
Why?
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 36 | 0.060 |
Why?
| Leukocytes, Mononuclear | 2 | 2015 | 113 | 0.060 |
Why?
| Body Weight | 1 | 2006 | 513 | 0.060 |
Why?
| Interleukin-2 | 1 | 2004 | 70 | 0.060 |
Why?
| Cystitis | 1 | 2004 | 17 | 0.060 |
Why?
| Tumor Suppressor Proteins | 1 | 2004 | 127 | 0.060 |
Why?
| Protein Processing, Post-Translational | 1 | 2005 | 154 | 0.060 |
Why?
| Pancreatic Pseudocyst | 1 | 2003 | 7 | 0.060 |
Why?
| Protozoan Proteins | 1 | 2004 | 32 | 0.060 |
Why?
| Jaundice, Obstructive | 1 | 2003 | 6 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2004 | 166 | 0.050 |
Why?
| Lidocaine | 1 | 2003 | 48 | 0.050 |
Why?
| Polymerase Chain Reaction | 1 | 2004 | 456 | 0.050 |
Why?
| Recombinant Fusion Proteins | 1 | 2004 | 183 | 0.050 |
Why?
| Cell Division | 1 | 2004 | 293 | 0.050 |
Why?
| Anesthetics, Local | 1 | 2003 | 74 | 0.050 |
Why?
| Hemorrhage | 1 | 2004 | 196 | 0.050 |
Why?
| Recombinant Proteins | 1 | 2004 | 480 | 0.050 |
Why?
| Oocytes | 1 | 2003 | 73 | 0.050 |
Why?
| Acute Disease | 3 | 2008 | 368 | 0.050 |
Why?
| Hepatocytes | 2 | 2013 | 179 | 0.050 |
Why?
| Amphetamines | 1 | 2002 | 27 | 0.050 |
Why?
| Indoles | 1 | 2024 | 273 | 0.050 |
Why?
| Phencyclidine | 1 | 2002 | 35 | 0.050 |
Why?
| Excitatory Amino Acid Antagonists | 1 | 2002 | 50 | 0.050 |
Why?
| Parkinsonian Disorders | 1 | 2001 | 10 | 0.050 |
Why?
| Dinoprostone | 2 | 2014 | 53 | 0.050 |
Why?
| Proto-Oncogene Proteins c-fos | 1 | 2001 | 61 | 0.050 |
Why?
| Dopamine Uptake Inhibitors | 1 | 2002 | 55 | 0.050 |
Why?
| Proto-Oncogene Proteins c-jun | 1 | 2001 | 75 | 0.050 |
Why?
| Proteins | 1 | 2004 | 348 | 0.050 |
Why?
| Asthma | 1 | 2005 | 282 | 0.050 |
Why?
| Receptors, N-Methyl-D-Aspartate | 1 | 2002 | 127 | 0.050 |
Why?
| Proto-Oncogene Proteins c-akt | 2 | 2014 | 155 | 0.050 |
Why?
| Molecular Targeted Therapy | 1 | 2021 | 121 | 0.040 |
Why?
| Infusions, Intra-Arterial | 2 | 2014 | 15 | 0.040 |
Why?
| Mitomycin | 2 | 2014 | 20 | 0.040 |
Why?
| Hepatic Artery | 2 | 2014 | 20 | 0.040 |
Why?
| Fluorouracil | 2 | 2014 | 55 | 0.040 |
Why?
| Hepatitis B Surface Antigens | 2 | 2013 | 9 | 0.040 |
Why?
| Disease Management | 1 | 2021 | 175 | 0.040 |
Why?
| Transfection | 2 | 2013 | 354 | 0.040 |
Why?
| Inflammation | 1 | 2003 | 608 | 0.040 |
Why?
| Predictive Value of Tests | 2 | 2012 | 921 | 0.040 |
Why?
| Lymphocytes | 1 | 2020 | 154 | 0.040 |
Why?
| Neutrophils | 1 | 2020 | 148 | 0.040 |
Why?
| Neoplasm Metastasis | 1 | 2019 | 235 | 0.040 |
Why?
| Reference Values | 2 | 2012 | 309 | 0.040 |
Why?
| Cell Movement | 3 | 2003 | 245 | 0.040 |
Why?
| Incidence | 2 | 2014 | 1000 | 0.030 |
Why?
| Calcium | 3 | 2003 | 400 | 0.030 |
Why?
| Brain | 2 | 2002 | 1311 | 0.030 |
Why?
| Amino Acid Sequence | 2 | 2010 | 576 | 0.030 |
Why?
| Probability | 2 | 2009 | 164 | 0.030 |
Why?
| Smoke | 1 | 2015 | 18 | 0.030 |
Why?
| Fluorescent Antibody Technique | 1 | 2014 | 112 | 0.030 |
Why?
| Interferon-alpha | 1 | 2014 | 49 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2014 | 141 | 0.030 |
Why?
| Viral Load | 1 | 2014 | 76 | 0.030 |
Why?
| Drug Resistance, Viral | 1 | 2013 | 7 | 0.030 |
Why?
| Hepatitis B e Antigens | 1 | 2013 | 4 | 0.030 |
Why?
| Appendectomy | 1 | 2014 | 32 | 0.030 |
Why?
| Transcriptional Activation | 1 | 2014 | 121 | 0.030 |
Why?
| Early Detection of Cancer | 1 | 2015 | 164 | 0.030 |
Why?
| Depression, Chemical | 2 | 2003 | 14 | 0.030 |
Why?
| Pelvis | 1 | 2014 | 67 | 0.030 |
Why?
| PPAR gamma | 1 | 2014 | 72 | 0.030 |
Why?
| Adenoviridae | 1 | 2013 | 49 | 0.030 |
Why?
| Abdomen | 1 | 2014 | 77 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 181 | 0.030 |
Why?
| Promoter Regions, Genetic | 2 | 2006 | 466 | 0.030 |
Why?
| Neoplastic Stem Cells | 1 | 2014 | 100 | 0.030 |
Why?
| Proportional Hazards Models | 2 | 2004 | 408 | 0.030 |
Why?
| Immunophenotyping | 1 | 2013 | 111 | 0.030 |
Why?
| Genetic Vectors | 1 | 2013 | 126 | 0.030 |
Why?
| Genome, Viral | 1 | 2013 | 78 | 0.030 |
Why?
| Tomography, X-Ray Computed | 2 | 2009 | 1160 | 0.030 |
Why?
| Blotting, Western | 1 | 2014 | 587 | 0.030 |
Why?
| Dependovirus | 1 | 2013 | 103 | 0.030 |
Why?
| Elasticity | 1 | 2012 | 20 | 0.030 |
Why?
| Albuterol | 2 | 2003 | 56 | 0.030 |
Why?
| Platelet Count | 1 | 2012 | 74 | 0.030 |
Why?
| Ubiquitination | 1 | 2012 | 40 | 0.030 |
Why?
| Alanine Transaminase | 1 | 2012 | 120 | 0.020 |
Why?
| Liver Function Tests | 1 | 2012 | 46 | 0.020 |
Why?
| RNA, Small Interfering | 1 | 2012 | 210 | 0.020 |
Why?
| Dopamine | 2 | 2003 | 171 | 0.020 |
Why?
| Base Sequence | 1 | 2012 | 653 | 0.020 |
Why?
| Drug Resistance, Bacterial | 1 | 2011 | 73 | 0.020 |
Why?
| Cerebral Cortex | 2 | 2002 | 195 | 0.020 |
Why?
| Blotting, Southern | 1 | 2010 | 43 | 0.020 |
Why?
| Blotting, Northern | 1 | 2010 | 110 | 0.020 |
Why?
| Sequence Deletion | 1 | 2010 | 69 | 0.020 |
Why?
| Hyperamylasemia | 1 | 2008 | 1 | 0.020 |
Why?
| Fatty Alcohols | 1 | 2008 | 2 | 0.020 |
Why?
| Mice, Inbred ICR | 1 | 2008 | 22 | 0.020 |
Why?
| I-kappa B Proteins | 1 | 2008 | 16 | 0.020 |
Why?
| Metabolic Clearance Rate | 1 | 2009 | 69 | 0.020 |
Why?
| Radionuclide Imaging | 1 | 2009 | 116 | 0.020 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 81 | 0.020 |
Why?
| Statistics, Nonparametric | 1 | 2009 | 193 | 0.020 |
Why?
| Liver Regeneration | 1 | 2008 | 47 | 0.020 |
Why?
| Hyperplasia | 1 | 2008 | 96 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2009 | 213 | 0.020 |
Why?
| Bacterial Infections | 1 | 2009 | 93 | 0.020 |
Why?
| Phosphatidylinositol 3-Kinases | 1 | 2008 | 139 | 0.020 |
Why?
| Cell Nucleus | 1 | 2008 | 186 | 0.020 |
Why?
| Mucous Membrane | 1 | 2007 | 28 | 0.020 |
Why?
| Duodenum | 1 | 2007 | 35 | 0.020 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 197 | 0.020 |
Why?
| Nitric Oxide | 1 | 2009 | 259 | 0.020 |
Why?
| Esophagus | 1 | 2007 | 82 | 0.020 |
Why?
| Flavones | 1 | 2006 | 5 | 0.020 |
Why?
| Dactinomycin | 1 | 2006 | 23 | 0.020 |
Why?
| Receptors, Aryl Hydrocarbon | 1 | 2006 | 25 | 0.020 |
Why?
| S100 Proteins | 1 | 2006 | 34 | 0.020 |
Why?
| RNA Processing, Post-Transcriptional | 1 | 2006 | 24 | 0.020 |
Why?
| Treatment Failure | 1 | 2006 | 116 | 0.020 |
Why?
| DNA, Complementary | 1 | 2006 | 133 | 0.020 |
Why?
| Emergencies | 1 | 2006 | 80 | 0.020 |
Why?
| Chemokine CCL17 | 1 | 2005 | 1 | 0.020 |
Why?
| Chemokine CCL22 | 1 | 2005 | 2 | 0.020 |
Why?
| Peak Expiratory Flow Rate | 1 | 2005 | 9 | 0.020 |
Why?
| Skin | 1 | 2008 | 416 | 0.020 |
Why?
| Sulfides | 1 | 2005 | 28 | 0.020 |
Why?
| Cyclopropanes | 1 | 2005 | 24 | 0.020 |
Why?
| Th2 Cells | 1 | 2005 | 22 | 0.020 |
Why?
| Acids | 1 | 2005 | 11 | 0.020 |
Why?
| Stress, Psychological | 1 | 2007 | 260 | 0.020 |
Why?
| Respiratory Function Tests | 1 | 2005 | 88 | 0.020 |
Why?
| Drug Resistance | 1 | 2005 | 64 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2008 | 1041 | 0.020 |
Why?
| RNA | 1 | 2006 | 166 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 2005 | 177 | 0.020 |
Why?
| alpha-Fetoproteins | 1 | 2004 | 15 | 0.020 |
Why?
| Hemostasis, Surgical | 1 | 2004 | 12 | 0.020 |
Why?
| Leucovorin | 1 | 2004 | 20 | 0.020 |
Why?
| Hepatitis C Antibodies | 1 | 2004 | 20 | 0.020 |
Why?
| Hepatectomy | 1 | 2004 | 22 | 0.010 |
Why?
| Transcription Factors | 1 | 2008 | 563 | 0.010 |
Why?
| Endoscopes, Gastrointestinal | 1 | 2004 | 3 | 0.010 |
Why?
| Omeprazole | 1 | 2004 | 17 | 0.010 |
Why?
| Virulence Factors | 1 | 2005 | 79 | 0.010 |
Why?
| Cardiolipins | 1 | 2004 | 2 | 0.010 |
Why?
| Dizziness | 1 | 2004 | 13 | 0.010 |
Why?
| Hydronephrosis | 1 | 2004 | 12 | 0.010 |
Why?
| Exanthema | 1 | 2004 | 31 | 0.010 |
Why?
| Pancreatitis, Alcoholic | 1 | 2003 | 2 | 0.010 |
Why?
| Ribosomal Proteins | 1 | 2004 | 25 | 0.010 |
Why?
| Chemokine CCL4 | 1 | 2003 | 5 | 0.010 |
Why?
| Chemokine CCL3 | 1 | 2003 | 8 | 0.010 |
Why?
| Double-Blind Method | 1 | 2005 | 682 | 0.010 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 102 | 0.010 |
Why?
| Autoantibodies | 1 | 2004 | 114 | 0.010 |
Why?
| Survival Analysis | 1 | 2004 | 670 | 0.010 |
Why?
| Dopamine Antagonists | 1 | 2002 | 22 | 0.010 |
Why?
| L-Lactate Dehydrogenase | 1 | 2002 | 70 | 0.010 |
Why?
| Binding, Competitive | 1 | 2002 | 94 | 0.010 |
Why?
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2001 | 5 | 0.010 |
Why?
| Tyrosine 3-Monooxygenase | 1 | 2001 | 10 | 0.010 |
Why?
| Neostriatum | 1 | 2001 | 10 | 0.010 |
Why?
| Glycine | 1 | 2002 | 78 | 0.010 |
Why?
| Cell Death | 1 | 2002 | 174 | 0.010 |
Why?
| Cell Membrane | 1 | 2002 | 249 | 0.010 |
Why?
| Cerebellum | 1 | 2001 | 132 | 0.010 |
Why?
| Kinetics | 1 | 2002 | 634 | 0.010 |
Why?
| Postoperative Complications | 1 | 2004 | 1027 | 0.010 |
Why?
| Child | 1 | 2005 | 6862 | 0.010 |
Why?
|
|
Hsu's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|